Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: Randomised controlled trial in primary care

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Selak, Vanessa ^a   Elley, C Raina ^a   Bullen, Chris ^a   Crengle, Sue ^a   Wadham, Angela ^a   Rafter, Natasha ^a   Parag, Varsha ^a   Harwood, Matire ^a   Doughty, Robert N ^a   Arroll, Bruce ^a   Milne, Richard J ^a   Bramley, Dale ^b   Bryant, Linda ^a   Jackson, Rod ^a   Rodgers, Anthony ^c  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b WAITEMATA DISTRICT HEALTH BOARD   (New Zealand)

^c GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS SIMVASTATIN PLUS LISINOPRIL PLUS ATENOLOL; ACETYLSALICYLIC ACID PLUS SIMVASTATIN PLUS LISINOPRIL PLUS HYDROCHLOROTHIAZIDE; CARDIOVASCULAR AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GENERAL PRACTICE; HEALTH SURVEY; HIGH RISK PATIENT; HUMAN; INDIGENOUS PEOPLE; MAJOR CLINICAL STUDY; NEW ZEALAND; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LISINOPRIL; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NEW ZEALAND; PRIMARY HEALTH CARE; REGRESSION ANALYSIS; RISK FACTORS; SIMVASTATIN; YOUNG ADULT;

EID: 84901723858     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3318     Document Type: Article

References (29)

1. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:1-52.
2. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Monique Verschuren WM, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur J Prev Cardiol 2012;19:585-667.
3. Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458-73.
4. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231-43.
5. University of Auckland, Health Quality & Safety Commission. Cardiovascular outcomes Health Quality & Safety Commission atlas of healthcare variation. 2012. www.hqsc.govt.nz.
6. World Health Organization. Secondary prevention of non-communicable disease in low and middle income countries through community-based and health service interventions. Wellcome Trust meeting report 1-3 Aug 2001. WHO, 2002.
7. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;360:2-3. (Pubitemid 34756482)
8. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419-24.
9. Elley C, Gupta AK, Webster R, Selak V, Jun M, Patel A, et al. The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials. PLoS One 2012;7:E52145.
10. Patel A, Cass A, Peiris D, Usherwood T, Brown A, Jan S, et al. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Eur J Prev Cardiol 2014; published online 27 Mar.
11. Thom S, Poulter NR, Field J, Patel A, Prabhakaran D, Stanton A, et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD. The UMPIRE randomised clinical trial. JAMA 2013;310:918-29.
12. Virdee SK, Greenfield SM, Fletcher K, McManus RJ, Hobbs FD, Mant J. Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study. BMJ Open 2013;3:e002498.
13. Viera AJ, Sheridan SL, Edwards T, Soliman EZ, Harris R, Furberg CD. Acceptance of a polypill approach to prevent cardiovascular disease among a sample of U.S. physicians. Prev Med 2011;52:10-5.
14. Holt S. New Zealand general practitioners' opinions of the polypill concept. N Z Med J 2009;122:116-7.
15. Bryant L, Martini N, Chan J, Chang L, Marmoush A, Robinson B, et al. Could the polypill improve adherence? The patient perspective. J Prim Health Care 2013;5:28-35.
16. Ministry for Culture and Heritage. Read the Treaty. 2012. www.nzhistory.net.nz/politics/treaty/read-the-treaty/english-text.
17. Webster R, Patel A, Billot L, Cass A, Burch C, Neal B, et al. Prospective meta-analysis of trials comparing fixed dose combination based care with usual care in individuals at high cardiovascular risk: the SPACE Collaboration. Int J Cardiol 2013;170:30-5.
18. Selak V, Elley C, Crengle S, Harwood M, Doughty R, Arroll B, et al. Improving adherence using combination therapy (IMPACT): design and protocol of a randomised controlled trial in primary care. Contemp Clin Trials 2011;32:909-15.
19. Selak V, Crengle S, Elley C, Wadham A, Harwood M, Rafter N, et al. Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial. Int J Equity Health 2013;12:44.
20. New Zealand Guidelines Group. Evidence-based best practice guideline. The assessment and management of cardiovascular risk. NZGG, 2003.
21. New Zealand Guidelines Group. New Zealand Cardiovacsular Guidelines Handbook: A summary resource for primary care practitioners. Wellington: NZGG, 2009.
22. Perkins MRV, Devlin NJ, Hansen P. The validity and reliability of EQ-5D health state valuations in a survey of Maori. Qual Life Res 2004;13:271-4. (Pubitemid 38315241)
23. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
24. Mehta S, Wells S, Riddell T, Kerr A, Pylypchuk R, Marshall R, et al. Under-utilisation of preventive medication in patients with cardiovascular disease is greatest in younger age groups (PREDICT-CVD 15). J Prim Health Care 2011;3:93-101.
25. Sanz G, Fuster V, Guzman L, Guglietta A, Arnaiz J, Martinez F, et al. The Fixed-dose Combination Drug for Secondary Cardiovascular Prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives. Am Heart J 2011;162:811-7.
26. Zamorano J, Erdine S, Pavia A, Kim J, Al-Khadra A, Westergaard M, et al. Proactive multiple cardiovascular risk factor management compared with usual care in patients with hypertension and additional risk factors: the CRUCIAL trial Curr Med Res Opin 2011;27:821-33.
27. Dresser G, Nelson S, Mahon J, Zou G, Vandervoort M, Wong C, et al. Simplified therapeutic intervention to control hypertension and hypercholesterolemia: a cluster randomized controlled trial (STITCH2). J Hypertens 2013;31:1702-13.
28. National Institute for Health and Care Excellence. Secondary prevention of coronary heart disease. 2010. [Indicator ID NM07 QOF ID: CHD006.] 2014. www.nice.org.uk/aboutnice/qof/indicators-detail.jsp?summary=13071.
29. Doyle C, Lennox L, Bell D. A systematic review of evidence on the links between patient experience and clinical safety and effectiveness BMJ Open 2012;3:e001570.